Loading stock…

Groupe Bruxelles Lambert SA (GBLB) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

GBLBGroupe Bruxelles Lambert

Revenue FY25$7.4B

GROWTH RATING↗

VERY WEAK13 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+0%4

EPS growth, FY28E+2%4

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 9%/yr over the last 3 years; forecasts see it cooling to 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 87% of companies worldwide.

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

GBLBGroupe Bruxelles Lambert

Total return Current13.5%

Price return Current−8.5%

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-13%3

YTD return-6%4

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return-8%4

3-year return+10%3

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 8% over the past year, now 18% below its 52-week high. That is right in line with the market.

Returns sit at the market level so far this year (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+10% over three years and -16% over five), behind 70% of the market.

The stock is underperforming over the past month (-9%) and over three months (-13%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on e Bruxelles. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GBLBGroupe Bruxelles Lambert

Revenue FY25$7.4B

GROWTH RATING↗

VERY WEAK13 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+9%6

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+2%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+0%4

EPS growth, FY28E+2%4

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 9%/yr over the last 3 years; forecasts see it cooling to 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 87% of companies worldwide.

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 2%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

GBLBGroupe Bruxelles Lambert

Total return Current13.5%

Price return Current−8.5%

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-13%3

YTD return-6%4

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return-8%4

3-year return+10%3

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 8% over the past year, now 18% below its 52-week high. That is right in line with the market.

Returns sit at the market level so far this year (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+10% over three years and -16% over five), behind 70% of the market.

The stock is underperforming over the past month (-9%) and over three months (-13%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on e Bruxelles. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Groupe Bruxelles Lambert SA

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on e Bruxelles. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on e Bruxelles. Get the full investment case.

Premium